USPTO serial 90836111
CLARIFY
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- LOOK, JEFFREY J
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CLARIFY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Courtney Thompson
Courtney Thompson FREDRIKSON & BYRON60 S. 6TH STREET, SUITE 1500MINNEAPOLIS, MN 55402United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 010 | Real time Polymerase Chain Reaction lyophilized products for medical laboratories, namely, analyzers and apparatus for testing blood or bodily fluids for medical diagnostic purposes; Nasopharyngeal testing devices in the nature of probes for detection of infectious disease; Medical diagnostic testing apparatus for detection of nucleic acid from SARS-CoV-2; Medical diagnostic testing apparatus for testing for Influenza A, Influenza B, SARS, Covid-19, SARS-CoV-2, Coronavirus, and respiratory illnesses; Cell-based medical diagnostic testing apparatus for testing for Influenza A, Influenza B, SARS, Covid-19, SARS-CoV-2, Coronavirus, and respiratory illnesses; Rapid medical diagnostic testing apparatus for testing for Influenza A, Influenza B, Covid-19, SARS-CoV-2, Coronavirus, and respiratory illnesses; Medical diagnostic testing apparatus for testing for Influenza A, Influenza B, SARS, Covid-19, SARS-CoV- 2, Coronavirus, and respiratory illnesses for point of care, laboratory, and home use; Medical diagnostic antigen testing apparatus for testing for Human papillomavirus (HPV), Gene Factor V, Factor II Mutation, MTHFR Enzyme (C677T and A1298C), Coagulation FV, CC 13910 Genotype (Lactose Activity), HLA-B27 Blood Test, Ureaplasma, Mycoplasma Hominis, Mycoplasma genitalium, Gonorrhea, Ureaplasma Urealyticum, Celiac Disease, Tuberculosis, Clostridioides, MRSA (Staph Infection), HSV, Herpes Zoster (Shingles), Monkeypox, Polio, T-Cell Antibodies, Hepatitis B, Hepatitis C, Human Immunodeficiency Virus, Treponema Pallidum, Helicobacter Pylori, Malaria, Vibrio Cholerae, Dengue Virus, Rotavirus, Adenovirus, Group A Streptococcus, Chlamydia, Salmonella, Zika, Influenza A, Influenza B, Chagas, Chikungunya,HCG, FSH Menopause, Male Fertility, Human Chronic Gonadotrophin, LH Ovulation, Amphetamine, Barbiturates, Benzodiazepine, Cocaine, MDMA, Morphine (MOR), Opiates(OPI), Methadone (MTD), Tricyclic Antidepressants, Tetrahydrocannabinol (THC), Buprenorphine (BUP), Oxycodone (Oxy), Ketamine(KET), Phencyclidine (PCP), Marijuana (K2), Fentanyl (FYL), Fatty Acid, Troponin, Creatine Kinase Isoenzymnes, Myoglobin, C Reactive Protein, Covid-19, SARS-CoV-2, Coronavirus, Cancer, Staphylococcus,Blood Disorders, Vitamin levels, Respiratory Disease, SARS, Urinary Infections, Fertility, Cardiac Markers, Tumor Markers, Drug Abuse, Digestive and Immune Disorders, Sexually Transmitted Diseases (STD), Herpes, Infectious Diseases, and parvo; Rapid medical diagnostic antigen testing apparatus for testing for Human papillomavirus (HPV), Gene Factor V, Factor II Mutation, MTHFR Enzyme (C677T and A1298C), Coagulation FV, CC 13910 Genotype (Lactose Activity), HLA-B27 Blood Test, Ureaplasma, Mycoplasma Hominis, Mycoplasma genitalium, Gonorrhea, Ureaplasma Urealyticum, Celiac Disease, Tuberculosis, Clostridioides, MRSA (Staph Infection), HSV, Herpes Zoster (Shingles), Monkeypox, Polio, T-Cell Antibodies, Hepatitis B, Hepatitis C, Human Immunodeficiency Virus, Treponema Pallidum, Helicobacter Pylori, Malaria, Vibrio Cholerae, Dengue Virus, Rotavirus, Adenovirus, Group A Streptococcus, Chlamydia, Salmonella, Zika, Influenza A, Influenza B, Chagas, Chikungunya,HCG, FSH Menopause, Male Fertility, Human Chronic Gonadotrophin, LH Ovulation, Amphetamine, Barbiturates, Benzodiazepine, Cocaine, MDMA, Morphine (MOR), Opiates(OPI), Methadone (MTD), Tricyclic Antidepressants, Tetrahydrocannabinol (THC), Buprenorphine (BUP), Oxycodone (Oxy), Ketamine(KET), Phencyclidine (PCP), Marijuana (K2), Fentanyl (FYL), Fatty Acid, Troponin, Creatine Kinase Isoenzymnes, Myoglobin, C Reactive Protein, Covid-19, SARS-CoV-2, Coronavirus, Cancer, Staphylococcus,Blood Disorders, Vitamin levels, Respiratory Disease, SARS, Urinary Infections, Fertility, Cardiac Markers, Tumor Markers, Drug Abuse, Digestive and Immune Disorders, Sexually Transmitted Diseases (STD), Herpes, Infectious Diseases, and parvo; Medical diagnostic antigen testing apparatus for testing for Human papillomavirus (HPV), Gene Factor V, Factor II Mutation, MTHFR Enzyme (C677T and A1298C), Coagulation FV, CC 13910 Genotype (Lactose Activity), HLA-B27 Blood Test, Ureaplasma, Mycoplasma Hominis, Mycoplasma genitalium, Gonorrhea, Ureaplasma Urealyticum, Celiac Disease, Tuberculosis, Clostridioides, MRSA (Staph Infection), HSV, Herpes Zoster (Shingles), Monkeypox, Polio, T-Cell Antibodies, Hepatitis B, Hepatitis C, Human Immunodeficiency Virus, Treponema Pallidum, Helicobacter Pylori, Malaria, Vibrio Cholerae, Dengue Virus, Rotavirus, Adenovirus, Group A Streptococcus, Chlamydia, Salmonella, Zika, Influenza A, Influenza B, Chagas, Chikungunya,HCG, FSH Menopause, Male Fertility, Human Chronic Gonadotrophin, LH Ovulation, Amphetamine, Barbiturates, Benzodiazepine, Cocaine, MDMA, Morphine (MOR), Opiates(OPI), Methadone (MTD), Tricyclic Antidepressants, Tetrahydrocannabinol (THC), Buprenorphine (BUP), Oxycodone (Oxy), Ketamine(KET), Phencyclidine (PCP), Marijuana (K2), Fentanyl (FYL), Fatty Acid, Troponin, Creatine Kinase Isoenzymnes, Myoglobin, C Reactive Protein, Covid-19, SARS-CoV-2, Coronavirus, Cancer, Staphylococcus,Blood Disorders, Vitamin levels, Respiratory Disease, SARS, Urinary Infections, Fertility, Cardiac Markers, Tumor Markers, Drug Abuse, Digestive and Immune Disorders, Sexually Transmitted Diseases (STD), Herpes, Infectious Diseases, and parvo for point of care, laboratory, and home use; Medical diagnostic testing apparatus for medical oncology use; Rapid medical diagnostic testing apparatus for medical oncology use; Medical diagnostic testing apparatus for medical oncology use for oncology for point of care, laboratory, and home use; Medical diagnostic testing apparatus to test for cardiac markers; Medical diagnostic testing apparatus for conducting antibody tests; Rapid medical diagnostic testing apparatus for conducting antibody tests; Medical diagnostic antibody diagnostic testing apparatus for conducting antibody tests for point of care, laboratory, and home use; Medical diagnostic testing apparatus to check for the presence and amount of vitamin D; Rapid medical diagnostic testing apparatus to check for the presence and amount of Vitamin D; Medical diagnostic testing apparatus to check for the presence and amount of Vitamin D for point of care, laboratory, and home use; Medical diagnostic testing apparatus to check for the presence and amount of opioids; Rapid medical diagnostic testing apparatus to check for the presence and amount of opioids; Medical diagnostic testing apparatus to check for the presence and amount of opioids for point of care, laboratory, and home use; Testing kits comprised of medical devices and diagnostic reagents and assays for testing bodily fluids, blood, DNA, RNA, and skin; Testing kits comprised of medical devices and diagnostic reagents and assays for rapid testing bodily fluids, blood, DNA, RNA, and skin; Testing kits comprised of medical devices and diagnostic reagents and assays for testing bodily fluids, blood, DNA, RNA, and skin for point of care, laboratory, and home use; Medical diagnostic testing apparatus to check for the presence and size of tumors; Rapid medical diagnostic testing apparatus to check for the presence and size of tumors; Medical diagnostic testing apparatus to check for the presence and size of tumors for point of care, laboratory, and home use; Rapid, single-use molecular diagnostic test kit comprised of medical testing apparatus, reagents, assays for the qualitative detection of SARS-CoV-2 RNA from self-collected nasal swab specimens; Rapid, single-use molecular diagnostic test kit comprised of medical testing apparatus, reagents, assays for the qualitative detection of SARS-CoV-2 RNA with isothermal amplification (LAMP) and test results displayed via LED indicators; Rapid, single-use molecular diagnostic test kit comprised of medical testing apparatus, reagents, assays for the qualitative detection of SARS-CoV-2 RNA with Positive Internal Control (PIC) and Lysis Internal Control (LIC) contained within the test unit; Syndromic infectious disease testing devices for medical use; Syndromic Infectious disease testing devices for medical use for testing for severe acute respiratory syndrome; Nucleic acid testing devices for medical use for testing for qualitative detection of respiratory viral and bacterial nucleic acids | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 29, 2025 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 29, 2025 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 21, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 20, 2025 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Oct 20, 2025 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| May 28, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 27, 2025 | EXT5 | SOU EXTENSION 5 FILED | — |
| Mar 3, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 27, 2024 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Nov 26, 2024 | EXT4 | SOU EXTENSION 4 FILED | — |
| Nov 26, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 24, 2024 | EX3G | SOU EXTENSION 3 GRANTED | — |
| May 24, 2024 | EXT3 | SOU EXTENSION 3 FILED | — |
| May 24, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 24, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 22, 2023 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Nov 22, 2023 | EXT2 | SOU EXTENSION 2 FILED | — |
| Nov 22, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 20, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 18, 2023 | EX1G | SOU EXTENSION 1 GRANTED | — |
| May 18, 2023 | EXT1 | SOU EXTENSION 1 FILED | — |
| May 18, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 29, 2022 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 4, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 4, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 14, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 26, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 10, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 9, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 9, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 9, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 9, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 9, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 8, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 21, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 28, 2021 | TAEA | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | — |
| Jul 28, 2021 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jul 22, 2021 | NWAP | NEW APPLICATION ENTERED | — |